Post

STCube Pharma – Research Scientist (Immuno oncology)

STCube Pharmaceuticals seeks a Research Scientist to advance preclinical programs within STCube Pharmaceuticals to the clinical trial stage.

Immune oncology, the therapeutic recruitment of the host immune system to defeat cancer, is the fastest growing sector of oncology therapy today because it is more effective and safer than conventional therapies. STCube Pharmaceuticals discovers and develops therapies against novel immune oncology targets. We operate on the cutting edge of this exciting and fast-paced field.

This opportunity is for a full-time Research Scientist to join our team at our research facility located in Gaithersburg, Maryland. Must have the ability to work in a collaborative, fast-paced team environment.

The successful Research Scientist candidate will possess a PhD with research experience in immunity, inflammation, cell biology, oncology, or a closely-related field. Please highlight your experience in the following areas:

–        Immune-Modulatory Target Discovery and Validation

–        T cell, B cell, Macrophage, Cancer Cell Biology

–        Antibody Development

–        Syngeneic Mouse Cancer Models

–        Immunohistochemistry, Immunofluorescence, Multispectral Staining, Confocal Microscopy

–        Flow Cytometry, CyTOF, Nanostring

STCube Pharmaceuticals offers a competitive salary and stock option package. We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status, protected veteran status, or any other characteristic protected by law.

Please send your resume or CV to recruitusa@stcube.com

 

PeopleBio R&D Center – Senior Research Scientist (Neuroscience)

PeopleBio provides pathfinding bio-products that inspire the diagnosis and treatment for neurodegenerative diseases through unconventional thinking and innovative work place. Founded in 2002, PeopleBio is a biotech company specialized in developing diagnostics for protein misfolding diseases with its proprietary technology, Multimer Detection System (MDS). Our technical advance in the development of tests for the early detection of protein-based diseases is recognized by global R&D networks and has established research cooperation with governmental health organizations, universities and pharmaceutical companies over the world.

 

 

Job title: Senior Research Scientist (Neuroscience)

Work place: PeopleBio R&D Center (242 Pangyo-ro, Bundang-gu, Seongnam, Korea)

 

Work scopes

– In-depth research in the field of neuronal diseases

– Publications and conference presentations

– R&D project planning, execution, and evaluation

– Study design

 

Qualifications

– Ph.D. in Neuroscience

– Strong speaking and writing skills in English

 

Salary & benefits

– 50,000,000 ~ 75,000,000 KRW per annum

– Health insurance, industrial accident insurance, national pension plan, employment insurance

 

근무 지역

  • 피플바이오 R&D Center (경기도 성남시 분당구 판교로 242 판교디지털센터)

전형 절차

  • 지원: 2017년 10월 20일 ~ 10월 20일
  • 1차: 서류전형 (합격자에 한하여 10월 30일 이후 통보)
  • 2차: 면접

접수 방법

  • 이메일 접수: people@peoplebio.net
  • 문의: 031-526-7825 혹은 people@peoplebio.net (담당자: 김신원 팀장)

제출 서류

  • 지원서 (정해진 양식 없음), 논문(pdf) 및 초록목록

Samyang Biopharm Recruitment

We are seeking a candidate that is passionate about innovative drug development and recognized as a globally experienced scientific leader in the field of Biologics.

 

 

  • Position: Research Head
  • Company: Samyang Biopharmaceutical Corp.
  • Location: Pankyo, Korea

 

 

[Job Description]

 

  • Screening, identifying and optimizing therapeutic biologics to have internal research pipeline with overall research strategy and direction
  • Lead and drive the research progress for biological products
  • Achieve goals of new product research, especially in-licensing opportunities in collaboration with Business Development
  • Establishing annual/long-term goals of research activities
  • Taking full research responsibility for optimal project execution and portfolio development

 

[Professional Experience / Qualifications]

 

  • A Ph.D. in Biology, Biochemistry, Protein Engineering, Immunology, Pharmaceutical Sciences, or equivalent Bio-Pharmaceutical industry experience
  • A minimum of 15 years of experience in pharmaceutical industry R&D with a major pharmaceutical, biotechnological or a generic pharmaceutical company
  • Strong know-how in the generation/screening of biological products and characteristics of therapeutic proteins
  • International/global work experience
  • Broad experience in management and project leadership
  • Business and collaboration mind set

 

[Contact]

 

Leading Researcher to Deliver Highly Anticipated Keynote Address on Gene Therapy at SITC 2017

MILWAUKEE – On the heels of the U.S. government’s approval of a groundbreaking gene therapy for treating cancer, a leading researcher in the field is set to deliver a highly anticipated keynote address on chimeric antigen receptor T cells, or ‘CAR T’ to kick off the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting.

Stephan Grupp, MD, PhD, the Director of Cancer Immunotherapy and Cell Therapy/Transplant Section at the Children’s Hospital of Pennsylvania in Philadelphia, will deliver his keynote speech, “The CAR T Revolution in Leukemia” on Friday, Nov. 10, 2017 at SITC 2017. The Annual Meeting takes place Nov. 10-12 in National Harbor, Md. Dr. Grupp’s presentation will focus on CAR T, which is a historic, first-of-its-kind gene therapy approved by the U.S. Food and Drug Administration (FDA) on Aug. 30, 2017 that supports the use of tisagenlecleucel in certain pediatric and young adult patients with acute lymphoblastic leukemia (ALL).

“Knowing that incredible advances in CAR T cell therapies were being made by SITC member researchers like Dr. Grupp and Dr. Carl June of the University of Pennsylvania,” said SITC President Lisa H. Butterfield, PhD, “SITC leaders decided in January that a keynote lecture on CAR T cells would really kick off an exciting and productive Annual Meeting for our attendees.”

Preceded by two days of Pre-Conference Programs on Nov. 8-9, which include a basic primer course on tumor immunology and cancer immunotherapy, a grant writing workshop, and other events, the three-day Annual Meeting will feature numerous cutting-edge presentations from leading experts in the field reporting the tremendous progress being made in cancer immunotherapy research.

Paul Sondel, MD, PhD, a professor and renowned researcher at the University of Wisconsin-Madison, will deliver the keynote speech on Saturday, Nov. 11, 2017 entitled, “Activation of Innate and Adaptive Immunity as an In Situ Cancer Vaccine.” Dr. Sondel is the 2017 recipient of the Richard V. Smalley, MD Memorial Award and Lectureship, the society’s most distinguished award honoring a luminary in the field who has significantly contributed to the advancement of cancer immunotherapy research.

“The 32nd Annual Meeting & Pre-Conference Programs is set to become the most highly attended SITC meeting ever,” Butterfield said. “A major reason why is researchers like Stephan Grupp, who have made their life’s work using the immune system to find a cure for cancer.”

Learn more about SITC 2017 and register to join the society in National Harbor this November by visiting the SITC 2017 Annual Meeting website.

About SITC The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit www.sitcancer.org.

KUCCLS (한미 생명과학 협력 컨퍼런스) Nov 2 – 4, 2017

2017년 한미 생명과학 협력컨퍼런스가 여러 후원기관들의 협찬을 받아 11월 2일에서 4일까지 2박3일동안 메릴랜드 락빌에서 개최됩니다.

이번 컨퍼런스에서는 합성 신약과 바이오로직스의 미국내 개발 및 승인과 관련된 미국정부의 인허가과정, 특허출원등 신약개발과 제약 산업 전반에 걸친 주제들을 다루는 프로그램이 준비되고 있읍니다. 원천연구에서 상용화까지의 전과정에 대한 전문가들의 발표와 네트워킹및 협력과제를 만들수있는 시간도 계획되고 있읍니다. 또한 채용 및 커리어에 관한 정보공유기회도 마련되어 있습니다.

아울러 이번 해에는 컨퍼런스 마지막날 NIH-KSA (Korean Scientist Association)와 함께 특별히 The 9th Annual Bioscience and Engineering symposium (ABES)를 공동개최합니다. 많은 성원과 참석을 부탁드립니다. 저희 홈피와 폐북에 계속 준비상황이 업데잇되니 참고하시기 바랍니다.

KUCCLS 2017 organizing committee
KAPAL (Korean- American Professional Association in Life Sciences)